期刊文献+

食欲抑制剂和药物诱导的肺动脉高压 被引量:3

Appetite suppressants and drugs associated pulmonary arterial hypertension
原文传递
导出
摘要 上世纪60年代起,食欲抑制剂与肺动脉高压(PAH)的相关性引起关注。本文综述食欲抑制剂和药物导致的PAH的流行病学资料、临床研究及其导致PAH发病的机制假说,探讨其疾病进展及预后。 In the 1960s,the use of appetite suppressants caused a transient incident of pulmonary arterial hypertension in western countries.Since then the case reports and basic researches have revealed a close relationship between appetite suppressants and pulmonary arterial hypertension.This review describes the epidemic features and clinical studies on appetite suppressant and drug induced pulmonary arterial hypertension,as well as the underlying mechanisms.The progression and prognosis of the disease also be discussed.
出处 《世界临床药物》 CAS 2013年第5期266-270,共5页 World Clinical Drug
关键词 肺动脉高压 食欲抑制剂 不良反应 pulmonary arterial hypertension appetite suppressant adverse reaction
  • 相关文献

参考文献46

  • 1Schwingshackl H, Amor H, Dienstl F. "Primary" pulmonary hypertension in 7 younger women. Possibility of relationship with the administration of aminorexfumarate[J]. Dtsch Med Wochenschr, 1969,94(13) :639-645.
  • 2Simon H, Felix R. Reversible pulmonary arterial hypertension after medication of aminorexfumarate[J]. Med Klin, 1977, 72 (41) :1685-1688.
  • 3Brenot F, Herve P, Petitpretz P, et al. Primary pulmonary hypertension and fenfluramine useJ J]. Br HeartJ, 1993, 70 (6): 537-541.
  • 4Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension[J]. N EnglJ Med, 1996,335 (9): 609-616.
  • 5荆志成,程显声,韩志岩,杨宏,裴卫东,高国栋.盐酸芬氟拉明致原发性肺动脉高压[J].中华医学杂志,2002,82(19):1362-1363. 被引量:4
  • 6Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis:lessons for the future in pathogenesis[J]. Respir Res, 2002, 11 (3): 9.
  • 7Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermineJ J]. N EnglJ Med, 1997,337 (9): 602-606.
  • 8Humbert M, Deng Z, Simonneau G, et al. BMPR2 germ line mutations in pulmonary hypertension associated with fenfluramine derivatives[J]. Eur RespirJ, 2002, 20 (3) :518-523.
  • 9Dempsie Y, MacLean MR. Pulmonary hypertension: therapeutic targets within the serotonin system[J]. BrJ Pharmacol, 2008, 155 (4) :455-462.
  • 10Rothman RB, Baumann MH. Setotonin releasing agents. Neurochemical, therapeutic and adverse effects[J]. Pharmacol Biochem Behav, 2002, 71 (4) :825-836.

二级参考文献7

  • 1Simonneau G, Fartoukh M, Sitbon O,et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest,1998,195s-199s.
  • 2Gurtner HP. Chronishe pulmonale hypertonie vasularen ursprungs,plexogene pulmonale arteriopathei under appetizügler aminorex. Schweiz Med Wochenschr,1985,782-789.
  • 3Douglas JG,MunroJF,Kitchin AH,et al. Pulmonary hypertension and fenfluramine. BMJ,1981,881-883.
  • 4Brenot F,Hervé P,Petitpretz P,et al. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993,537-541.
  • 5Abenhaim L,Moride Y,Brenot F,et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med,1996,609-616.
  • 6Mark EJ,Patalas ED,Chang HT,et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med,1997,602-606.
  • 7McTavish D,Heel RC. Dexfenfluramine,a review of its pharmacological properties and therapeutic potential in obesity. Drugs, 1992,713-733.

共引文献3

同被引文献46

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部